ArticleThe American journal of tropical medicine and hygiene2013
Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis.
Article in The American journal of tropical medicine and hygiene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.EBioMedicine · 2020Trial
- Effectiveness of Short-Course Meglumine Antimoniate (Glucantime®) for Treatment of Visceral Leishmaniasis: A 13-Year, Multistage, Non-Inferiority Study in Iran.The American journal of tropical medicine and hygiene · 2017Trial
- Blood parasite load by qPCR as therapeutic monitoring in visceral leishmaniasis patients in Brazil: a case series study.Revista da Sociedade Brasileira de Medicina Tropical · 2023Article
- Diagnostic Performance of Three rK39 Rapid Diagnostic Tests and Two Direct Agglutination Tests for the Diagnosis of Visceral Leishmaniasis in Southern Iran.Journal of tropical medicine · 2022Article
- Antibody and cytokine levels in visceral leishmaniasis patients with varied parasitemia before, during, and after treatment in patients admitted to Arba Minch General Hospital, southern Ethiopia.PLoS neglected tropical diseases · 2021Article
- Pediatric visceral leishmaniasis: a retrospective study to propose the diagnostic tests algorithm in southern Iran.Parasitology research · 2021Article
- Frequency of Leishmania spp. infection among HIV-infected patients living in an urban area in Brazil: a cross-sectional study.BMC infectious diseases · 2020Article
- Whole Blood Stimulation Assay as a Treatment Outcome Monitoring Tool for VL Patients in Ethiopia: A Pilot Evaluation.Journal of immunology research · 2020Article
- Advances toward Diagnostic Tools for Managing Zoonotic Visceral Leishmaniasis.Trends in parasitology · 2018Review
- Autoantibodies in a Three-Year-Old Girl with Visceral Leishmaniasis: A Potential Diagnostic Pitfall.Case reports in infectious diseases · 2016Article
- Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Article
- Leishmaniases diagnosis: an update on the use of immunological and molecular tools.Cell & bioscience · 2015Article
- A novel molecular microbiologic technique for the rapid diagnosis of microbial invasion of the amniotic cavity and intra-amniotic infection in preterm labor with intact membranes.American journal of reproductive immunology (New York, N.Y. : 1989) · 2014Article
- Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment.Journal of translational internal medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meglumine antimoniate (Glucantime) remains the therapeutic cornerstone of visceral leishmaniasis (VL). Twenty-one VL patients were treated with Glucantime, extending for 1 week after defervescence. For monitoring the response, Leishmania infantum kinetoplast DNA loads were evaluated using real-time polymerase chain reaction (PCR) assay in the blood. The maximum duration of treatment was 14 days. The loads before treatment ranged from 8 to 1,300,000 parasites/mL (mean = 73,095 parasites/mL), and the mean values on days 3, 7, 14, 28, and 90 were 4,902, 506, 6.33, 0.26, and 0.14, respectively. The loads decline to < 1 parasite/mL for 16 (76%) and 20 (95%) patients on days 14 and 28, respectively, and they decline for all patients by day 90. Results showed a dramatic decrease of the parasite loads, although complete clearance was not accomplished at the end of treatment. Only one relapse (4.5%) was observed. The parasite load can also serve as a dependable index for monitoring the response to Glucantime.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.